Head to head
Exelixis vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: EXEL · VRTX
EXEL
Exelixis
64.63-1.82%
1-year price shape — +55% over the period
Quant Rating C · 89/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| EXEL | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 64.63 | 515.02 |
| Change today | -1.82% | -1.08% |
| 1-year return | +54.7% | +22.0% |
| Market cap | $15.77B | $130.58B |
| 52-week range | 39.71 – 73.69 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | 19.35 | 33.14 |
| P/E percentile, own 5-yr range | 32nd | 99th |
| P/B | 8.60 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | 2.78 | 15.32 |
| Net profit (TTM) | $678.35M | $3.88B |
| Revenue (TTM) | $2.50B | $12.95B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | +10.2% | +11.8% |
| Gross margin | 96.3% | 85.5% |
| Operating margin | 40.2% | 33.1% |
| Net margin | 35.5% | 30.7% |
| Free cash flow (TTM) | $1.14B | $3.20B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 103.2% | 96.8% |
| Insider activity (12mo) | 17 buy / 33 sell | 28 buy / 22 sell |
| Short interest (% of float) | 10.5% | 1.9% |
| Analyst consensus | 57% buy / 29% hold / 14% sell (7) | 95% buy / 5% hold (21) |
| Analyst price target | $65 (+1%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (89) | C (68) |
| Company | ||
| Employees | 4,600 | 6,400 |
| Founded | 1994 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.